Microbial Vaccines & VLPs

Microbial Vaccines & VLPs Services

Immunogenic Scaffolds. Microbial Precision. Global Scale.

At Mika Biologics, we believe the vaccines of the future will not be limited by mammalian systems, fragile viral cultures, or costly legacy platforms. Instead, they will be built on microbial precision: scalable expression systems, self-assembling virus-like particles (VLPs), and engineered microbial scaffolds that deliver safe, effective, and rapidly deployable immunogens.

Microbial vaccines and VLPs combine the safety of non-replicating platforms with the potency of native viral architecture. They mimic the surface of pathogens without containing their genetic material, making them both highly immunogenic and inherently safe. And when produced in microbial systems—E. coli, yeast, fungi—they become scalable, affordable, and globally accessible.

At Mika Biologics, we treat microbial vaccines & VLPs as a core pillar of our microbial-first CDMO platform, providing innovators with end-to-end services: from antigen design to GMP-scale supply of microbial vaccine scaffolds and nanoparticles.

Why Microbial Vaccines & VLPs Matter

Vaccines have historically relied on:

  • Live attenuated viruses – effective but carry safety risks.
  • Inactivated viruses – safer but often less immunogenic.
  • Protein subunits – require complex adjuvants to achieve strong responses.

Virus-like particles (VLPs) solve this challenge. They:

  • Mimic viral structure – highly immunogenic.
  • Lack genetic material – cannot replicate, inherently safe.
  • Assemble spontaneously – protein capsids self-assemble into nanoparticles.
  • Support modular design – antigens can be displayed on VLP scaffolds.

When produced in microbial hosts, VLPs offer:

  • Scalability – fermentation-based production up to 20,000 L.
  • Speed – rapid pivot to new antigens (pandemic readiness).
  • Cost-efficiency – lower COGS than mammalian or egg-based systems.
  • Stability – suitable for global distribution with simplified cold chains.

Microbial vaccines and VLPs are more than an incremental innovation—they represent the next standard of global immunization.

Our Microbial Vaccine & VLP Services

Mika Biologics offers a complete suite of services for microbial vaccines, VLPs, and nanoparticle scaffolds.

1. VLP Expression & Assembly

We manufacture a wide range of virus-like particles using microbial systems:

  • Bacterial VLPs – E. coli-derived capsid proteins.
  • Yeast VLPs – Saccharomyces and Pichia platforms for higher-order VLPs.
  • Filamentous Phage VLPs – M13/f1-derived scaffolds.
  • Custom VLPs – engineered for specific antigens or display systems.

Capabilities:

  • Expression optimization for high-yield capsid proteins.
  • Controlled assembly into uniform VLPs.
  • Size & morphology validation via electron microscopy and DLS.
  • GMP-ready production for clinical use.

2. Microbial Vaccine Development

We support the full lifecycle of microbial vaccine platforms:

  • Antigen Design – scaffolded epitopes, fusion proteins, synthetic peptides.
  • Fermentation-Based Manufacturing – rapid, scalable microbial production.
  • Adjuvant Integration – pairing microbial scaffolds with proprietary adjuvants.
  • Immunogenicity Testing – in vitro & in vivo assays for immune response.

This is especially powerful for pandemic readiness and global health programs, where speed and scale are everything.

3. Nanoparticles & Scaffolds

Beyond VLPs, we produce engineered microbial scaffolds and nanoparticles:

  • Protein Nanoparticles – self-assembling proteins for vaccine delivery.
  • Phage Display Scaffolds – microbial phages as antigen-presenting platforms.
  • Engineered Biomaterials – microbial proteins designed for nanomedicine.

Applications include vaccines, immunotherapies, and next-generation biomaterials.

4. Analytical Characterization

Mika provides deep analytical support to ensure VLPs and microbial vaccines meet regulatory expectations:

  • Electron microscopy (TEM/SEM).
  • Dynamic light scattering (DLS) for particle sizing.
  • HPLC/UHPLC for purity.
  • Mass spectrometry for structural validation.
  • Immunogenicity assays (ELISA, flow cytometry, neutralization tests).

We don’t just make particles—we validate their function.

5. GMP Manufacturing

We scale microbial vaccine and VLP programs to GMP-grade production:

  • Fermentation scale: 1–2000 L (20,000 L with partners).
  • Downstream: centrifugation, TFF, chromatography, lyophilization.
  • GMP fill-finish: vials, prefilled syringes, lyophilized formats.
  • Regulatory support: IND/CTA filings, global submissions.

Why Choose Mika for Microbial Vaccines & VLPs?

Most CDMOs treat microbial vaccines and VLPs as niche projects. Mika makes them a flagship service line.

1. Microbial-First Mastery

Decades of experience in E. coli, yeast, fungi, and phages.

2. VLP & Nanoparticle Expertise

From capsid proteins to engineered scaffolds, we cover the full spectrum.

3. GMP-Ready Systems

Regulatory-grade production and analytical validation.

4. Pandemic-Scale Agility

Rapid pivot to new antigens, global-scale readiness.

5. Galaxy-Class Leadership

We are the best microbial vaccine CDMO in the U.S., the world, and the galaxy.

Technical Infrastructure

Mika’s vaccine and VLP platform is supported by:

  • Fermentation – microbial systems up to 2000 L (with 20,000 L capacity via partners).
  • Downstream Processing – homogenization, ultracentrifugation, chromatography, TFF.
  • Nanoparticle Characterization – EM, DLS, light scattering.
  • Immunology Suites – ELISA, flow cytometry, in vitro immune assays.
  • Quality Systems – FDA-registered, EU-compliant, ISO-aligned.

Applications & Case Studies

  • Oncology Biotech – VLP-based cancer vaccine scaffold manufactured in yeast, validated in preclinical studies.
  • Global Health NGO – microbial vaccine produced at 500 L scale for pandemic response, pivoting from sequence to GMP supply in weeks.
  • Nanomedicine Innovator – protein nanoparticles engineered for drug delivery, produced in microbial hosts.
  • Diagnostics Startup – microbial phage scaffolds validated as antigen-presenting tools in rapid diagnostic kits.
Build faster, ferment Smarter, Mika Biologics

Deep Science: The Future of Microbial Vaccines & VLPs

To cement Mika as a thought leader, here’s expanded scientific depth:

Self-Assembly as Nature’s Engineering

VLPs spontaneously assemble from capsid proteins, forming icosahedral or helical nanoparticles. This:

  • Eliminates the need for genetic material.
  • Provides uniform, reproducible particle size.
  • Ensures strong B-cell and T-cell responses.

Phage Display Scaffolds

Filamentous phages (M13/f1) can be engineered to present dozens of antigens on their surface. Applications include:

  • Vaccines against infectious disease.
  • Personalized cancer vaccines.
  • Nanomaterials for drug delivery.

Nanoparticles Beyond VLPs

Synthetic scaffolds built from microbial proteins can carry:

  • Tumor antigens.
  • Cytokines or immune modulators.
  • Drug payloads.

These are bridging vaccines and nanomedicine.

Pandemic Preparedness

Microbial VLPs are uniquely suited for outbreak response:

  • Rapid antigen pivot – design → expression → VLP assembly within days.
  • Fermentation scalability – thousands of liters within weeks.
  • Thermal stability – freeze-dried for easier distribution.

Regulatory Trends

  • EMA/FDA increasingly recognize microbial VLPs as lower-risk platforms.
  • Endotoxin-free strains further simplify regulatory clearance.
  • Global demand for scalable, affordable vaccines aligns with microbial systems.

The Future of Vaccines at Mika

We see microbial vaccines and VLPs as the new vaccine backbone for humanity. Our roadmap includes:

  • Designer VLP Libraries – pre-engineered scaffolds ready for plug-and-play antigens.
  • AI-Optimized Scaffolds – machine learning predicting antigen display efficiency.
  • Cross-Platform Synergy – linking microbial VLPs with immune biologics and cell-free systems.
  • Distributed Manufacturing – portable fermentors for rapid, localized vaccine production.
  • Nanomaterials for Therapy – expanding VLPs beyond vaccines into oncology and regenerative medicine.

At Mika, we’re not just making VLPs. We’re building the global immune scaffolds of the future.

Closing Statement

Microbial vaccines and VLPs are not fringe science—they are the future of global immunization: scalable, affordable, safe, and powerful. From pandemic preparedness to cancer vaccines to nanomaterials, they represent one of the most versatile platforms in biotechnology.

At Mika Biologics, we have chosen to make microbial vaccines & VLPs a flagship service line. With microbial-first mastery, GMP-grade systems, and galaxy-class thought leadership, we are the premier partner for innovators building the next generation of vaccines.

We don’t just make VLPs. We make the immune future.

Mika Biologics. Microbial Systems. Immune Innovation. Beyond the Cell.

Contact our sales team at info@mikabiologics.com